- idUS
- Listar por autor
Listar por autor "Vázquez Morón, Juan María"
Mostrando ítems 1-4 de 4
-
Artículo
Effectiveness and safety of ustekinumab dose escalation in Crohn’s disease: a multicenter observational study
Olmedo Martín, Raúl Vicente; Vázquez Morón, Juan María; Martín Rodríguez, María del Mar; Lázaro Sáez, Marta; Hernández Martínez, Álvaro; Argüelles Arias, Federico (Aran Ediciones S.A., 2023)Background: ustekinumab has proven effective in Crohn’s disease (CD). However, some patients will partially respond or ...
-
Artículo
Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia
Hernández Martínez, Álvaro; Navajas Hernández, Pilar; Martín Rodríguez, María del Mar; Lázaro Sáez, Marta; Olmedo Martín, Raúl; Nuñez Ortiz, Andrea; Argüelles Arias, Federico; Vázquez Morón, Juan María (Aran Ediciones S.A., 2022)Background: tofacitinib is a Janus kinase inhibitor approved for the treatment of moderate-severe ulcerative colitis ...
-
Artículo
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
Guerra Veloz, María Fernanda; Vázquez Morón, Juan María; Belvis Jiménez, María Inmaculada; Pallares Manrique, Héctor; Valdés Delgado, Teresa; Castro Laria, Luisa; Merino Bohórquez, Vicente; Vilches Arenas, Ángel; Argüelles Arias, Federico (Aran Ediciones S.A., 2018)Background and aims: infliximab has changed the natural history of inflammatory bowel disease (IBD). The advent of ...
-
Artículo
Ustekinumab in Crohn’s disease: real-world outcomes and predictors of response
Lorenzo González, Laura; Valdés Delgado, Teresa; Vázquez Morón, Juan María; Castro Laria, Luisa; Leo Carnerero, Eduardo; Maldonado Pérez, María Belén; Sánchez Capilla, Damián; Pallarés Manrique, Héctor; Sáez Díaz, Antonia; Argüelles Arias, Federico (Aran Ediciones S.A., 2022)Background: ustekinumab is a monoclonal antibody that inhibits interleukins IL-12 and IL-23, and is approved for the ...